

News Releases

All Years

Search

Go

[Advanced Search](#)

NOV 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NOV 3, 2021

Inhibrx Announces Presentations at SITC 2021

NOV 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

OCT 28, 2021

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

SEP 13, 2021

Inhibrx Announces Participation in Upcoming Investor Conference

AUG 9, 2021

Inhibrx Reports Second Quarter 2021 Financial Results

JUN 21, 2021

Inhibrx Initiates a Potential Registration-Enabling Phase 2 Study of INBRX 100 in Conventional Chondrosarcoma Patients. Update

OF INBRX-109 IN CONVENTIONAL CHONDROSARCOMA PATIENTS, UPDATES DATA FOR ONGOING PHASE 1 STUDY AND ANNOUNCES AMENDED LOAN AGREEMENT WITH OXFORD

MAY 17, 2021

Inhibrx Announces Participation in Upcoming Investor Conferences

MAY 13, 2021

Inhibrx Reports First Quarter 2021 Financial Results

MAR 12, 2021

Inhibrx Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Announces Phase 1 Single Agent Dose Escalation Results for INBRX-105, a Novel Targeted 4-1BB Agonist

Show per
page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=10&o=50>